

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- **Prioritized:** Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- **Phased:** Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- **Published:** Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. **Here is how this deal stacks up.**

DEAL SUMMARY

Parties: Moderna and European Commission

Date: November 25, 2020

Terms of Agreement: Moderna reached an agreement with the European Commission to supply 80 million doses of their vaccine candidate to European Union (EU) Member States, with an option for the European Commission to request an additional 80 million doses. Financial details have not been disclosed.

METRIC	SCORE	RATIONALE
Prioritized 	1	80m doses would cover nearly 9% of the European Union's population with a 2-dose regimen, exceeding the 3% initial allocation threshold but within the threshold to prioritize the most vulnerable 20% population.
Phased 	1	The deal provides 80 million doses of the vaccine, and an option to request additional 80 million doses. Ideally, the deal will allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.
Published 	0	The EC has not listed details about the terms of deal and pricing online, but an EU official indicated the price per dose is less than \$19.50. Moderna have not disclosed their pricing model.

Total Score: 2 out of 6

The EU has negotiated strong conditions on liability and non-exclusivity in its Moderna contract. The deal partially ensures the initial supply of vaccines isn't monopolized by the EU. Subsequent deals could be improved specifying delivery timelines for the doses.

Moderna could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure additional doses aren't purchased before other countries have secured deals for portions of the initial supply.

▲ Impeding Equity

Advancing Equity ▲